论文部分内容阅读
目的探讨保守治疗晚期胃癌的临床疗效及安全性。方法回顾性分析我院收治的76例经病理确诊局部晚期或远处转移的老年晚期胃癌患者的临床资料,采用替吉奥胶囊联合奥沙利铂给予治疗。22d为一疗程,连用2个疗程后评价临床疗效和毒副反应。结果 76例患者中13例完全缓解(CR),30例部分缓解(PR),稳定(SD)20例,进展(PD)13例,总有效率(CR+PR)56.6%,临床受益率为82.9%。所有患者的主要毒副反应较轻,未影响治疗。结论奥沙利铂联合替吉奥胶囊治疗晚期胃癌的临床疗效显著,毒副反应小,值得在临床广泛推广。
Objective To investigate the clinical efficacy and safety of conservative treatment of advanced gastric cancer. Methods The clinical data of 76 patients with locally advanced or distant metastasis of advanced gastric cancer who were confirmed by pathology were retrospectively analyzed. The patients were treated with tigeorgile and oxaliplatin. 22d for a course of treatment, even after 2 courses of evaluation of clinical efficacy and toxicity. Results Of the 76 patients, 13 had complete remission (CR), 30 had partial response (PR), 20 had stable (SD) and 13 had progressive (PD). The total effective rate (CR + PR) was 56.6% 82.9%. The main side effects of all patients were mild, did not affect the treatment. Conclusion The clinical efficacy of oxaliplatin in combination with TIGI capsule in the treatment of advanced gastric cancer is significant, and the side effects are small. It is worth widely popularized in clinic.